A new preliminary study published in Nature suggests that COVID-19 vaccines might actually boost the immune system to make ...

New data suggest that early peanut exposure may cut the risk of allergic reactions. Newsweek asked experts what parents ...

Johnson & Johnson today announced plans to initiate the first head-to-head study comparing FcRn blockers for patients with generalized myasthenia gravis (gMG), which aims to affirm IMAAVYtm ...

Reviewers viewed the targeting of TFAM as innovative and the study's conclusions as potentially important (especially the effects on inflammation). However, the lack of evidence for a direct effect of ...

CoV-2, has led to the first approval of mRNA vaccines in humans. By producing the full-length SARS-CoV-2 Spike protein, they ...

Phase 3b LUCENT-URGE is the first study in inflammatory bowel disease to assess bowel urgency across three measures — severity, frequency and stool deferral time — reflecting the spectrum of its ...

First Phase 3 study (MajesTEC-3) of an investigational combination to show benefit in PFS and OS in relapsed/refractory multiple myeloma as early as second line ...

Responses were rapid and durable, and tumor shrinkage was observed in 82 percent of patients New findings from this investigational study build on the strength ...

BRAFTOVI + MEKTOVI continued to show a substantial median overall survival benefit of 47.6 months in treatment-naïve patients with BRAF V600E-mutant metastatic non-small cell lung cancer after ...

Levofloxacin-induced myopathy is a relatively under-recognized adverse effect. Here, we present a case of myopathy affecting ...

Once an antibody latches on to a pathogen, broadly neutralizing antibodies inactivate it (as their name implies). This is ...

(Nasdaq: CDNA) – a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients ...